Globus Medical

Ticker: GMED

Sector: Health Care Equipment & Supplies

Globus Medical

Globus Medical projects a long-term estimated earnings growth rate of 12.7% compared with 15.5% of the industry. More than 99% of shareholders have approved the deal with NuVasive. Globus Medical, Inc. has a market capitalization of $6.22 billion. Canaccord Genuity Group reaffirmed their “buy’s ‘buy” rating for Globus medical with a price objective set at $67 per share in their research note on March 28th this year. Bloomberg.com states that there are currently one sell, seven hold ratings and four buy rating levels - ArabaciDie Publication metic Genesis143 eater WebassembledPrivate presidentVER State of New Jersey Common Pension Fund Ds holdings in Globus Medical were worth $2,450,000 at the end of the most recent reporting period. Wellington Management Group LLP boosted its holdings in shares of Globus medical by 0.6% in the 1st quarter. Director Dan Lemaitre sold 43,450 shares of shares of Globeus Medical stock in a transaction. Globus Medical, Inc. (GMED) Statistics & Valuation Metrics - Stock Analysis. At close: Jul 21, 2023, 4:00 PM 62.37 +0.61 (0.99%) After-hours: $66.63 - 7.89% higher than current price. The salary for Sales Representative at Globus Medical is $60,000 annually. Medtronic, Stryker, Johnson & Johnson (Depuy Synthes), Globus medical Inc., Zimmer Biomet, Orthofix Holdings Inc., NuVasive. Globus Medical CEO David Paul is the founder and executive chairman of spine implant manufacturer Globus. Paul worked as an engineer for medical device giant Synthes before leaving in 2003.